Q1 2019 13F Holders as of 3/31/2019
-
Type / Class
-
Equity / Common Stock, par value $0.001
-
Shares outstanding
-
67.8M
-
Number of holders
-
38
-
Total 13F shares, excl. options
-
2.6M
-
Shares change
-
+2.5M
-
Total reported value, excl. options
-
$12M
-
Value change
-
+$11.5M
-
Number of buys
-
36
-
Number of sells
-
-1
-
Price
-
$4.92
Significant Holders of Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) as of Q1 2019
42 filings reported holding CLDX - Celldex Therapeutics, Inc. - Common Stock, par value $0.001 as of Q1 2019.
Celldex Therapeutics, Inc. - Common Stock, par value $0.001 (CLDX) has 38 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 2.6M shares
of 67.8M outstanding shares and own 3.84% of the company stock.
Largest 10 shareholders include RENAISSANCE TECHNOLOGIES LLC (545K shares), VANGUARD GROUP INC (488K shares), BlackRock Inc. (303K shares), DIMENSIONAL FUND ADVISORS LP (264K shares), TSP Capital Management Group, LLC (156K shares), ACADIAN ASSET MANAGEMENT LLC (147K shares), BRIDGEWAY CAPITAL MANAGEMENT INC (124K shares), GEODE CAPITAL MANAGEMENT, LLC (108K shares), D. E. Shaw & Co., Inc. (106K shares), and Invesco Ltd. (45.1K shares).
This table shows the top 38 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.